Bevacizumab is an antibody that inhibits the VEGF receptor and was investigated in combination with atezolizumab, an anti-PD-L1 antibody, for patients with ccRCC or sarcomatoid histology RCC in the IMmotion151 phase III trial [13]. The gene discussed is CD274; the disease is renal cell carcinoma.